Genus plc

LSE:GNS 株式レポート

時価総額：UK£1.5b

Genus 将来の成長

Future 基準チェック /06

Genusの収益は年間10.8%で減少すると予測されていますが、年間収益は年間1.8%で増加すると予測されています。EPS は年間 減少すると予測されています。自己資本利益率は 3 年後に10.7% 8.5%なると予測されています。

主要情報

-10.8%

収益成長率

-8.49%

EPS成長率

Biotechs 収益成長12.2%
収益成長率1.8%
将来の株主資本利益率10.74%
アナリストカバレッジ

Good

最終更新日14 Jul 2026

今後の成長に関する最新情報

Recent updates

ナラティブ更新 • Jul 07

GNS: Gene Editing Progress Will Drive Medium-Term Upside Potential

Analysts have updated their view on Genus with a revised price target of about £22.94 from £25.50, reflecting recalibrated assumptions on fair value, discount rate, revenue growth, profit margins and future P/E after a mix of bullish and neutral recent coverage. Analyst Commentary on Genus Recent coverage on Genus has been mixed, with a new bullish initiation from JPMorgan set against more neutral commentary from other houses.
ナラティブ更新 • Jun 22

GNS: Margin Discipline And New Bank Coverage Will Support Medium Term Upside

Analysts have maintained their fair value estimate for Genus at £37.00, with recent research indicating that this figure represents a balance between differing new views from JPMorgan and BNP Paribas on the stock's prospects. Analyst Commentary Recent coverage of Genus reflects a split in opinion, with some bullish analysts highlighting upside potential while others strike a more cautious, neutral tone.
ナラティブ更新 • Jun 05

GNS: Margin Discipline And Stable P/E Framework Will Drive Medium Term Upside

Genus’s analyst price target holds steady at £37.00 as analysts balance a modestly lower revenue growth outlook with slightly higher profit margin and P/E assumptions following mixed new coverage from JPMorgan and BNP Paribas. Analyst Commentary Recent research coverage has focused on how Genus’s current valuation lines up with its profit potential, with one new initiation from JPMorgan and another neutral initiation helping anchor the £37.00 analyst price target.
ナラティブ更新 • May 18

GNS: Bullish JPMorgan Initiation And Margin Outlook Will Drive Medium Term Upside

Analysts have reduced their fair value estimate for Genus from about £31.63 to roughly £31.28. This reflects a combination of slightly softer revenue growth assumptions, a modestly higher discount rate, and expectations for a stronger profit margin profile supported by a mix of bullish and neutral recent research views.
ナラティブ更新 • May 03

GNS: China Joint Venture Cash Inflow Will Drive Medium Term Upside

Analysts have kept the Genus fair value target steady at £37.00, while modestly adjusting underlying assumptions on discount rate, profit margin and future P/E to reflect a mix of bullish and neutral initiation views in recent research. Analyst Commentary Recent initiation coverage signals a mixed but generally constructive tone on Genus, with one major bank expressing clear optimism and others adopting a more neutral stance.
ナラティブ更新 • Apr 19

GNS: Gene Editing Breakthrough And China JV Will Drive Medium Term Upside

Analysts have lifted their fair value estimate for Genus from £35.00 to £37.00, citing updated assumptions on discount rates, growth, margins, and future P/E multiples reflected in recent Street research, including the £1.00 price target increase reported by Berenberg. Analyst Commentary Recent Street research on Genus points to a more constructive tone on the shares, with bullish analysts reflecting this in higher price targets and refreshed valuation work.
ナラティブ更新 • Apr 04

GNS: Gene Editing Progress And China JV Execution Will Shape Medium-Term Upside

Analysts have raised their price target for Genus by £1.00, citing updated assumptions on the discount rate, revenue growth, profit margin and future P/E as the key drivers behind the change. Analyst Commentary Bearish analysts view the higher price target and updated assumptions as leaving limited room for error.
ナラティブ更新 • Mar 20

GNS: China JV And Gene Editing Progress Will Drive Medium Term Upside

Analysts have nudged their price target on Genus up by £1.00, citing updated fair value and discount rate assumptions along with revised expectations for revenue growth, profit margins and future P/E as the key drivers for the change. Analyst Commentary Bullish Takeaways Bullish analysts see the £1.00 uplift in the price target as aligned with updated fair value work, suggesting that their revised assumptions on revenue growth and margins still support the current valuation framework.
ナラティブ更新 • Mar 06

GNS: China JV And Gene Editing Progress Will Support Medium Term Upside

Analysts have raised their price target on Genus by £1.00, supported by updated assumptions around fair value, discount rate, revenue growth, profit margin and future P/E multiples. Analyst Commentary Analysts lifting their fair value assumptions for Genus are signalling a shift in how they view the balance between the company’s growth potential and execution risks.
ナラティブ更新 • Feb 20

GNS: Gene Editing Execution And Regulatory Timelines Will Constrain Medium-Term Upside

Analysts have raised their fair value estimate for Genus from £24.00 to £25.50, reflecting updated assumptions on revenue growth, profit margins and the potential of its gene editing technology as highlighted in recent research. Analyst Commentary Recent street research on Genus highlights a mix of optimism around its gene editing platform and caution around how that potential is reflected in the share price.
ナラティブ更新 • Feb 06

GNS: Gene Editing Progress And China JV Will Shape Balanced Medium Term Outlook

Genus's updated analyst price target reflects a modest uplift in estimated fair value to £30.82, supported by higher assumed revenue growth and a richer future P/E multiple, even as analysts factor in a slightly higher discount rate and softer profit margins. Analyst Commentary Recent Street research on Genus points to a generally constructive stance, with analysts revisiting their models and price targets as they reassess the company’s growth potential and execution risks.
ナラティブ更新 • Jan 23

GNS: Gene Editing Breakthrough Will Drive Medium Term Upside Potential

Narrative Update on Genus Analysts have lifted their price target on Genus to £31.00 from £29.00, citing the company's gene editing technology and its perceived medium term upside potential as key reasons for the change. Analyst Commentary Bullish analysts are highlighting Genus as a name with medium term upside potential, underpinned by its gene editing capabilities and recent supportive price target work.
ナラティブ更新 • Jan 08

GNS: Gene Editing Potential Will Drive Balanced Medium-Term Opportunity And Execution Risk

Narrative Update Analysts now see Genus as fairly valued in a range of £30.50 to £31.00. This reflects a modestly revised P/E assumption, slightly higher revenue growth and profit margin expectations, and a growing focus on the potential of its gene editing technology for medium term upside.
分析記事 • Jan 06

Calculating The Fair Value Of Genus plc (LON:GNS)

Key Insights Genus' estimated fair value is UK£21.95 based on 2 Stage Free Cash Flow to Equity Current share price of...
ナラティブ更新 • Dec 22

GNS: Gene Editing Platform Will Shape Balanced Medium-Term Upside And Execution Risks

Genus's analyst price target has been raised from about £18.80 to £24.00 per share as analysts highlight the upside from its gene editing platform and reaffirm Buy ratings alongside recent target hikes from major banks. Analyst Commentary Recent research updates underscore a constructive stance on Genus, with buy ratings supported by the view that its gene editing platform could materially expand medium term earnings power.
ナラティブ更新 • Dec 08

GNS: Gene Editing Platform Will Drive Medium Term Upside Despite Execution Risks

Analysts have nudged their price target on Genus higher to £31.00 from £29.00, citing increasing confidence in the medium term upside from its gene editing platform and a modest uplift in expected profitability, even as growth assumptions normalize slightly. Analyst Commentary Bullish analysts highlight that the uplift in price targets reflects growing conviction that Genus can translate its gene editing capabilities into sustained, above-market earnings growth over the medium term.
ナラティブ更新 • Nov 24

GNS: Future China Joint Venture Will Improve Near-Term Shareholder Returns

Analysts have increased their price target for Genus from £29.00 to £31.00. This reflects greater confidence in the company's outlook despite moderating growth forecasts and a slightly higher discount rate.
分析記事 • Nov 15

Benign Growth For Genus plc (LON:GNS) Underpins Its Share Price

You may think that with a price-to-sales (or "P/S") ratio of 2.4x Genus plc ( LON:GNS ) is definitely a stock worth...
分析記事 • Oct 28

Genus (LON:GNS) Is Paying Out A Dividend Of £0.217

Genus plc's ( LON:GNS ) investors are due to receive a payment of £0.217 per share on 5th of December. Including this...
分析記事 • Oct 18

We Like Genus' (LON:GNS) Earnings For More Than Just Statutory Profit

Genus plc's ( LON:GNS ) solid earnings announcement recently didn't do much to the stock price. Our analysis suggests...
分析記事 • Oct 11

Genus (LON:GNS) Is Due To Pay A Dividend Of £0.217

Genus plc ( LON:GNS ) has announced that it will pay a dividend of £0.217 per share on the 5th of December. This means...
ナラティブ更新 • Sep 10

FDA Approval Of PRP Program In 2025 Will Open Significant Revenue Stream

The upward revision in Genus’s price target reflects improved analyst expectations, driven by notable increases in both forecast revenue growth (from 4.0% to 4.9% per annum) and net profit margin (from 7.88% to 8.73%), resulting in a new fair value of £27.97. What's in the News Genus and Beijing Capital Agribusiness Co. (BCA) have accelerated the formation of a Chinese joint venture to commercialise PRRS 2 Resistant Pig (PRP), with BCA holding 51% and Genus 49%.
分析記事 • Sep 07

Genus (LON:GNS) Is Due To Pay A Dividend Of £0.217

The board of Genus plc ( LON:GNS ) has announced that it will pay a dividend of £0.217 per share on the 5th of...
分析記事 • Jul 25

There's No Escaping Genus plc's (LON:GNS) Muted Revenues Despite A 25% Share Price Rise

Despite an already strong run, Genus plc ( LON:GNS ) shares have been powering on, with a gain of 25% in the last...
分析記事 • Jul 22

Estimating The Fair Value Of Genus plc (LON:GNS)

Key Insights The projected fair value for Genus is UK£25.58 based on 2 Stage Free Cash Flow to Equity Genus' UK£24.10...
分析記事 • May 10

Genus plc (LON:GNS) Stock Catapults 36% Though Its Price And Business Still Lag The Industry

Genus plc ( LON:GNS ) shareholders would be excited to see that the share price has had a great month, posting a 36...
分析記事 • Apr 18

An Intrinsic Calculation For Genus plc (LON:GNS) Suggests It's 21% Undervalued

Key Insights The projected fair value for Genus is UK£20.55 based on 2 Stage Free Cash Flow to Equity Genus is...
User avatar
新しいナラティブ • Feb 11

Regulatory Approvals And Sustainability Initiatives Will Strengthen Future Market Position

Expansion in the porcine business and PRRS resistant pig commercialization boosts revenue stability and growth through innovation and market penetration.
分析記事 • Feb 01

There's No Escaping Genus plc's (LON:GNS) Muted Revenues Despite A 25% Share Price Rise

Genus plc ( LON:GNS ) shareholders are no doubt pleased to see that the share price has bounced 25% in the last month...
分析記事 • Nov 20

Lacklustre Performance Is Driving Genus plc's (LON:GNS) Low P/S

Genus plc's ( LON:GNS ) price-to-sales (or "P/S") ratio of 1.7x might make it look like a strong buy right now compared...
分析記事 • Oct 23

Genus (LON:GNS) Has Affirmed Its Dividend Of £0.217

Genus plc ( LON:GNS ) will pay a dividend of £0.217 on the 6th of December. This payment means the dividend yield will...
分析記事 • Oct 22

There May Be Some Bright Spots In Genus' (LON:GNS) Earnings

The market for Genus plc's ( LON:GNS ) shares didn't move much after it posted weak earnings recently. We did some...
分析記事 • Sep 08

Genus plc Just Missed EPS By 72%: Here's What Analysts Think Will Happen Next

Genus plc ( LON:GNS ) shareholders are probably feeling a little disappointed, since its shares fell 4.1% to UK£17.10...
分析記事 • Jun 16

The Price Is Right For Genus plc (LON:GNS)

Genus plc's ( LON:GNS ) price-to-earnings (or "P/E") ratio of 33.6x might make it look like a strong sell right now...
分析記事 • Apr 20

Estimating The Fair Value Of Genus plc (LON:GNS)

Key Insights Genus' estimated fair value is UK£18.59 based on 2 Stage Free Cash Flow to Equity Genus' UK£17.18 share...
分析記事 • Mar 25

Is Genus (LON:GNS) Using Too Much Debt?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
分析記事 • Mar 05

With A 26% Price Drop For Genus plc (LON:GNS) You'll Still Get What You Pay For

Genus plc ( LON:GNS ) shares have had a horrible month, losing 26% after a relatively good period beforehand. The drop...
分析記事 • Feb 25

Genus (LON:GNS) Has Affirmed Its Dividend Of £0.103

Genus plc ( LON:GNS ) has announced that it will pay a dividend of £0.103 per share on the 28th of March. The dividend...
分析記事 • Jan 17

Getting In Cheap On Genus plc (LON:GNS) Might Be Difficult

Genus plc's ( LON:GNS ) price-to-earnings (or "P/E") ratio of 44x might make it look like a strong sell right now...
分析記事 • Dec 10

Does This Valuation Of Genus plc (LON:GNS) Imply Investors Are Overpaying?

Key Insights The projected fair value for Genus is UK£15.63 based on 2 Stage Free Cash Flow to Equity Genus is...

業績と収益の成長予測

LSE:GNS - アナリストの将来予測と過去の財務データ ( )GBP Millions
日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数
6/30/202973673801201
6/30/202868964661008
6/30/20276655762938
6/30/2026672185586910
12/31/2025672484664N/A
9/30/2025672334766N/A
6/30/2025673194967N/A
3/31/202567284058N/A
12/31/2024672-43149N/A
9/30/202467021840N/A
6/30/20246698530N/A
3/31/202467121837N/A
12/31/2023673331045N/A
9/30/2023681331348N/A
6/30/2023690331550N/A
3/31/202367634-142N/A
12/31/202266234-1835N/A
9/30/202262838-2534N/A
6/30/202259341-3134N/A
3/31/202258239-2039N/A
12/31/202157037-943N/A
9/30/2021572421355N/A
6/30/2021574473468N/A
3/31/2021570454270N/A
12/31/2020566425072N/A
9/30/2020559394066N/A
6/30/2020551353060N/A
3/31/2020536372555N/A
12/31/2019520391949N/A
9/30/201950423N/A41N/A
6/30/20194898N/A33N/A
3/31/20194801N/A35N/A
12/31/2018471-7N/A37N/A
9/30/201847018N/A40N/A
6/30/201847043N/A43N/A
3/31/201847355N/A42N/A
12/31/201747667N/A41N/A
9/30/201746750N/A38N/A
6/30/201745933N/A35N/A
3/31/201744140N/A34N/A
12/31/201642247N/A33N/A
9/30/201640548N/A31N/A
6/30/201638849N/A30N/A
3/31/201638840N/A25N/A
12/31/201538831N/A21N/A
9/30/201539335N/A28N/A

アナリストによる今後の成長予測

収入対貯蓄率: GNSの収益は今後 3 年間で減少すると予測されています (年間-10.8% )。

収益対市場: GNSの収益は今後 3 年間で減少すると予測されています (年間-10.8% )。

高成長収益: GNSの収益は今後 3 年間で減少すると予測されています。

収益対市場: GNSの収益 ( 1.8% ) UK市場 ( 4.6% ) よりも低い成長が予測されています。

高い収益成長: GNSの収益 ( 1.8% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: GNSの 自己資本利益率 は、3年後には低くなると予測されています ( 10.7 %)。

成長企業の発掘

7D

1Y

7D

1Y

7D

1Y

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2026/07/16 02:37
終値2026/07/16 00:00
収益2025/12/31
年間収益2025/06/30

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

このレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Genus plc 8 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。19

アナリスト機関
Robert ChantryBerenberg
Adam TomlinsonBerenberg
Matthew LloydBNP Paribas